Replimune Group (NASDAQ:REPL) Stock Jumps 8.3% – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL)’s share price traded up 8.3% during trading on Monday. The company traded as high as $19.09 and last traded at $19.0740. Approximately 4,814,670 shares were traded during mid-day trading, an increase of 11% from the average daily volume of 4,332,466 shares. The stock had previously closed at $17.61.

Analyst Ratings Changes

Several research firms recently commented on REPL. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a report on Monday, October 5th. Finally, Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Replimune Group has an average rating of “Moderate Buy” and an average price target of $14.33.

Replimune Group Trading Up 10.7%

The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -6.99 and a beta of 0.93. The business has a 50-day moving average of $13.58 and a two-hundred day moving average of $9.35. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. Research analysts predict that Replimune Group, Inc. will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the transaction, the chief executive officer owned 708,151 shares in the company, valued at $9,184,718.47. This trade represents a 5.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 11,448 shares of Replimune Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,480.56. Following the transaction, the chief financial officer directly owned 225,108 shares of the company’s stock, valued at approximately $2,919,650.76. The trade was a 4.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 79,124 shares of company stock valued at $1,038,364. 5.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Replimune Group in the second quarter valued at approximately $99,171,000. Opaleye Management Inc. acquired a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $15,332,000. EcoR1 Capital LLC bought a new position in Replimune Group during the first quarter worth about $7,650,000. ADAR1 Capital Management LLC acquired a new position in shares of Replimune Group in the second quarter valued at approximately $7,260,000. Finally, Jefferies Financial Group Inc. bought a new position in Replimune Group during the 2nd quarter worth about $5,485,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.